EDUCATION, AWARENESS, SUPPORT & ORGAN DONATION

What is Hepatitis?

Get an overview of Hepatitis and learn more about the three main viruses: Hepatitis A, B, and C.

Donations

Help enhance our education and
awareness programs.

Hepatitis C News
  • Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment
    READ NEWS
  • FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment
    READ NEWS
  • FDA OKs new drug to treat all forms of hepatitis C
    READ NEWS
  • Hepatitis C Virus Cases Nearly Triple in 5 years
    READ NEWS
  • Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
    READ NEWS
  • Hepatitis Tied to Parkinson’s Risk
    READ NEWS
  • Cirrhosis Increasing Among Hepatitis C Patients, According to Large US Study
    READ NEWS
  • Hepatitis C – Hepatitis Central.Com
    READ NEWS
  • Primary care providers can effectively treat people with hepatitis C
    READ NEWS
  • VA Study Confirms High Cure Rates With Use Of New Hepatitis C Drugs
    READ NEWS
  • Hepatitis C virus and neurological damage
    READ NEWS
  • Over 1 million treated with highly effective hepatitis C medicines
    READ NEWS
  • Gilead and Massachusetts Agree to Rebates for Hep C Drugs
    READ NEWS
  • FDA approves Epclusa
    READ NEWS
  • Hepatitis C Antibody Screening in a Retail Pharmacy Setting: Local Testing and Linkage to Care via an HCV Management Specialist
    READ NEWS
  • Covering Costly HCV Tx: Who Makes that Call?
    READ NEWS
  • CDC Press Release: Hepatitis C Kills More Americans Than Any Other Infectious Disease
    READ NEWS
  • HCV Testing: CDC Recommendations Miss 25% of Infections
    READ NEWS
  • Merck's Zepatier shows high response rates in hep C trials
    READ NEWS
  • New hepatitis C regimen shows high cure rates: studies
    READ NEWS
  • Nearly one-third of patients with previous HCC recur after DAA therapy
    READ NEWS
  • FDA Approves Merck’s New Hepatitis C Treatment
    READ NEWS
  • AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
    READ NEWS
  • AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
    READ NEWS
  • AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
    READ NEWS
  • AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
    READ NEWS
  • Large Cure Rate for Patients with Hepatitis C May Have a Significant Impact on the Transplant Wait List
    READ NEWS
  • Nearly Half of Hepatitis C Patients on Medicaid Denied Coverage for Life-Saving Drugs, Penn Researchers Report
    READ NEWS
  • ALLY 3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin Demonstrates High Cure Rates in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis
    READ NEWS
  • The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C
    READ NEWS
  • Early HCV fibrosis suggests need for early treatment
    READ NEWS
  • Grazoprevir-elbasvir effective for hepatitis C in advanced chronic kidney disease
    READ NEWS
  • Gilead's Hepatitis C Drug Works Against All Strains in Trial
    READ NEWS
  • Therapy Respond Well to AbbVie Hepatitis C Treatment
    READ NEWS
  • White House Under Pressure To Promote Better Access For Hepatitis C Drugs
    READ NEWS

SEE ALL NEWS ARTICLES

Upcoming 2017 Events

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.



The information provided on this site is intended to support, not replace, the relationship that exists between a patient and his/her physician. Hepatitis C Association does not display commercial content or receive funding from advertising products or services.

Support line: 877-HELP-4-HEP (877-435-7443)
Born from 1945 - 1965? CDC recommends you get tested for Hepatitis C.  Get tested. Learn more: //www.cdc.gov/KnowMoreHepatitis/

 

 

 

For questions about Harvoni or Sovaldi providers & patients call 1-855-769-7284
Or visit the following websites:

www.harvoni.com

www.gilead.com

www.mysupportpath.com

 

Patient Advocate Foundation call 1-800-532-5274 or visit www.patientadvocate.org

 

For Questions about Viekira Pak
Call 1-844-2-PROCEED (1-844-277-6233)
or visit www.viekira.com

 

For questions about Olysio
Call 1-855-65-99747 or visit www.olysio.com

 

World Health Organization Hepatitus C Guidelines

 

Patient Assistance NOW

Home | What is hepatitis? | About Us | Who's Involved | Hepatitis C News | Upcoming Events | Gift Cards | Related Links

Noteworthy Bulletins | All the Joy | Contact Information| Privacy Statement | Support line 877-HELP-4-HEP (877-435-7443)

© 2015 Hepatitis C Association Inc, All rights reserved.